Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

INLYTA®(axitinib)

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

INLYTA® Quick Finder

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypertension

Advise patients that hypertension...

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypertension

Advise patients that hypertension may develop during INLYTA treatment and that blood pressure should be monitored regularly during treatment [see

Arterial/Venous Thromboembolic Events

Advise patients that arterial and venous thromboembolic events have been observed during INLYTA treatment and to inform their doctor if they experience symptoms suggestive of thromboembolic events [see

Hemorrhage

Advise patients that INLYTA may increase the risk of bleeding and to promptly inform their doctor of any bleeding episodes [see

Cardiac Failure

Advise patients that cardiac failure may develop during INLYTA treatment and that signs or symptoms of cardiac failure should be regularly monitored for during treatment [see

Gastrointestinal Disorders

Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during INLYTA treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking INLYTA [see

Abnormal Thyroid Function

Advise patients that abnormal thyroid function may develop during INLYTA treatment and to inform their doctor if symptoms of abnormal thyroid function occur [see

Risk of Impaired Wound Healing

Advise patients that INLYTA may impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedure [see

Reversible Posterior Leukoencephalopathy Syndrome

Advise patients to inform their doctor if they have worsening of neurological function consistent with RPLS (headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances) [see

Major Adverse Cardiovascular Events

Advise patients receiving INLYTA in combination with avelumab to contact their healthcare provider immediately for signs or symptoms of cardiovascular events including but not limited to new or worsening chest discomfort, dyspnea, or peripheral edema [see

Embryo-Fetal Toxicity

Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [see

Lactation

Advise patients not to breastfeed while taking INLYTA and for 2 weeks after receiving the last dose [see

Infertility

Advise males and females of reproductive potential that INLYTA may impair fertility [see

Concomitant Medications

Advise patients to inform their doctor of all concomitant medications, vitamins, or dietary and herbal supplements.


Did you find an answer to your question? Yes No

What is INLYTA?


  • in combination with avelumab or pembrolizumab as your first treatment.
  • alone when 1 prior drug treatment regimen for your RCC has not worked.
Before taking...

What is INLYTA?


  • in combination with avelumab or pembrolizumab as your first treatment.
  • alone when 1 prior drug treatment regimen for your RCC has not worked.
Before taking INLYTA, tell your healthcare provider about all of your medical conditions, including if you:
  • have high blood pressure
  • have thyroid problems
  • have liver problems
  • have a history of blood clots in your veins or arteries (types of blood vessels), including stroke, heart attack, or change in vision
  • have any bleeding problems
  • have a history of heart problems, including heart failure
  • have an unhealed wound
  • plan to have surgery or have had a recent surgery. You should stop taking INLYTA for at least 2 days before planned surgery. See " What are the possible side effects of INLYTA?"
For females, tell your healthcare provider if you:
  • are pregnant or plan to become pregnant. Taking INLYTA during pregnancy can harm your unborn baby. You should not become pregnant during treatment with INLYTA.
  • are able to become pregnant. You should have a pregnancy test before you start treatment with INLYTA. Use effective birth control during treatment and for 1 week after your last dose of INLYTA. Talk to your healthcare provider about birth control methods that you can use to prevent pregnancy during this time.
  • are breastfeeding or plan to breastfeed. It is not known if INLYTA passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after your last dose of INLYTA.
For males with female partners who are able to become pregnant:
  • Use effective birth control during treatment and for 1 week after your last dose of INLYTA.
  • If your female partner becomes pregnant during your treatment with INLYTA, tell your healthcare provider right away.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.
Talk with your healthcare provider before you start taking any new medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Did you find an answer to your question? Yes No

How should I take INLYTA?

  • Take INLYTA exactly as prescribed by your healthcare provider.
  • Your healthcare provider may change your dose if needed.
  • INLYTA can be taken with or without food.
  • Take INLYTA 2 times a day about 12 hours apart.
  • Swallow...

How should I take INLYTA?

  • Take INLYTA exactly as prescribed by your healthcare provider.
  • Your healthcare provider may change your dose if needed.
  • INLYTA can be taken with or without food.
  • Take INLYTA 2 times a day about 12 hours apart.
  • Swallow INLYTA tablets whole with a glass of water.
  • Your healthcare provider should check your blood pressure regularly during treatment with INLYTA.
  • If you vomit or miss a dose of INLYTA, take your next dose at your regular time. Do not take two doses at the same time.
  • If you take too much INLYTA, call your healthcare provider or go to the nearest hospital emergency room right away.
Did you find an answer to your question? Yes No

What should I avoid while taking INLYTA?

  • Do not drink grapefruit juice or eat grapefruit. Grapefruit may increase the amount of INLYTA in your blood.

What should I avoid while taking INLYTA?

  • Do not drink grapefruit juice or eat grapefruit. Grapefruit may increase the amount of INLYTA in your blood.
Did you find an answer to your question? Yes No

What are the possible side effects of INLYTA?


  • High blood pressure (hypertension). High blood pressure is common with INLYTA and may sometimes be severe. Your healthcare provider should check your blood pressure regularly during treatment with INLYTA...

What are the possible side effects of INLYTA?


  • High blood pressure (hypertension). High blood pressure is common with INLYTA and may sometimes be severe. Your healthcare provider should check your blood pressure regularly during treatment with INLYTA. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure, lower your dose, or stop your treatment with INLYTA.
  • Blood clots in your veins or arteries. INLYTA can cause blood clots which can be serious, and sometimes lead to death. Get emergency help and call your healthcare provider if you get any of the following symptoms:
  • chest pain or pressure
  • pain in your arms, back, neck or jaw
  • shortness of breath
  • numbness or weakness on one side of your body
  • trouble talking
  • headache
  • vision changes
  • Bleeding. INLYTA can cause bleeding which can be serious, and sometimes lead to death. Call your healthcare provider right away or get medical help if you develop any of the following signs or symptoms:
    • unexpected bleeding or bleeding that lasts a long time, such as:
  • unusual bleeding from the gums
  • menstrual bleeding or vaginal bleeding that is heavier than normal
  • bleeding that is severe or you cannot control
  • pink or brown urine
  • red or black stools (looks like tar)
  • bruises that happen without a known cause or get larger
  • cough up blood or blood clots
  • vomit blood or your vomit looks like "coffee grounds"
    • unexpected pain, swelling, or joint pain
    • headaches, feeling dizzy or weak
  • Heart failure. Your healthcare provider should check you for signs or symptoms of heart failure regularly during treatment with INLYTA. Heart failure can be serious and can sometimes lead to death. Tell your healthcare provider if you have any of the following symptoms during your treatment with INLYTA:
  • tiredness
  • swelling of your stomach-area (abdomen), legs or ankles
  • shortness of breath
  • protruding neck veins
  • Tear in your stomach or intestinal wall (perforation). A tear in your stomach or intestinal wall can be serious and can sometimes lead to death. Get medical help right away if you get the following symptoms:
    • severe stomach-area (abdominal) pain or stomach-area pain that does not go away
    • vomit blood
    • red or black stools
  • Thyroid gland problems. Your healthcare provider should do blood tests to check your thyroid gland function before and during your treatment with INLYTA. Tell your healthcare provider if you have any of the following symptoms during your treatment with INLYTA:
  • tiredness that worsens or that does not go away
  • feeling hot or cold
  • your voice deepens
  • weight gain or weight loss
  • hair loss
  • muscle cramps and aches
  • Risk of wound healing problems. Wounds may not heal properly during INLYTA treatment. Tell your healthcare provider if you plan to have any surgery before starting or during treatment with INLYTA.
    • You should stop taking INLYTA at least 2 days before planned surgery.
    • Your healthcare provider should tell you when you may start taking INLYTA again after surgery.
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS). A condition called reversible posterior leukoencephalopathy syndrome (RPLS) can happen during treatment with INLYTA. Call your healthcare provider right away if you get:
  • headache
  • seizures
  • weakness
  • confusion
  • high blood pressure
  • blindness or change in vision
  • problems thinking
  • Protein in your urine. Your healthcare provider should check your urine for protein before and during your treatment with INLYTA. If you develop protein in your urine, your healthcare provider may decrease your dose of INLYTA or stop your treatment.
  • Liver problems. Your healthcare provider will do blood tests before and during your treatment with INLYTA. Your healthcare provider may delay or stop your treatment with INLYTA if you develop severe liver problems.
  • Heart problems. When INLYTA is used with the medicine avelumab, severe heart problems can happen and can lead to death. Your healthcare provider will check you for heart problems during your treatment with INLYTA. Tell your healthcare provider right away or get medical help if you have any of the following symptoms:
  • swelling of your stomach-area, legs, hands feet or ankles
  • shortness of breath
  • nausea or vomiting
  • chest discomfort, including pain or pressure
  • weight gain
  • pain or discomfort in your arms, back, neck, or jaw
  • breaking out in a cold sweat
  • feeling lightheaded or dizzy
The most common side effects of INLYTA with avelumab include:
  • diarrhea
  • feeling tired
  • muscle and bone pain
  • nausea
  • mouth sores
  • rash, redness, itching, or peeling of your skin on your hands and feet
  • hoarseness
  • decreased appetite
  • low levels of thyroid hormone
  • rash
  • liver problems
  • cough
  • shortness of breath
  • stomach-area (abdomen) pain
  • headache
The most common side effects of INLYTA with pembrolizumab include:
  • diarrhea
  • feeling tired or weak
  • liver problems
  • low levels of thyroid hormone
  • decreased appetite
  • rash, redness, itching or peeling of your skin on your hands and feet
  • nausea
  • mouth sores or swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina
  • hoarseness
  • rash
  • cough
  • constipation
The most common side effects of INLYTA when used alone include:
  • diarrhea
  • feeling tired or weak
  • decreased appetite
  • nausea
  • hoarseness
  • rash, redness, itching or peeling of your skin on your hands and feet
  • decreased weight
  • vomiting
  • constipation
INLYTA may cause fertility problems in males and females, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.
These are not all of the possible side effects of INLYTA.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Did you find an answer to your question? Yes No

How should I store INLYTA?

Store INLYTA at room temperature between 68°F to 77°F (20°C to 25°C).

How should I store INLYTA?

Store INLYTA at room temperature between 68°F to 77°F (20°C to 25°C).

Did you find an answer to your question? Yes No

General information about the safe and effective use of INLYTA.


Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INLYTA for a condition for which it was not prescribed. Do not give INLYTA to other people,...

General information about the safe and effective use of INLYTA.


Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INLYTA for a condition for which it was not prescribed. Do not give INLYTA to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about INLYTA that is written for health professionals.

Did you find an answer to your question? Yes No

What are the ingredients in INLYTA?


Active ingredientInactive ingredients®

...

What are the ingredients in INLYTA?


Active ingredientInactive ingredients®

Logo

LAB-0439-6.0For more information, go to www.inlyta.com or call 8770744-5675
This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
Did you find an answer to your question? Yes No

Full Patient Information

...

Full Patient Information

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypertension

Advise patients that hypertension may develop during INLYTA treatment and that blood pressure should be monitored regularly during treatment [see

Arterial/Venous Thromboembolic Events

Advise patients that arterial and venous thromboembolic events have been observed during INLYTA treatment and to inform their doctor if they experience symptoms suggestive of thromboembolic events [see

Hemorrhage

Advise patients that INLYTA may increase the risk of bleeding and to promptly inform their doctor of any bleeding episodes [see

Cardiac Failure

Advise patients that cardiac failure may develop during INLYTA treatment and that signs or symptoms of cardiac failure should be regularly monitored for during treatment [see

Gastrointestinal Disorders

Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during INLYTA treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking INLYTA [see

Abnormal Thyroid Function

Advise patients that abnormal thyroid function may develop during INLYTA treatment and to inform their doctor if symptoms of abnormal thyroid function occur [see

Risk of Impaired Wound Healing

Advise patients that INLYTA may impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedure [see

Reversible Posterior Leukoencephalopathy Syndrome

Advise patients to inform their doctor if they have worsening of neurological function consistent with RPLS (headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances) [see

Major Adverse Cardiovascular Events

Advise patients receiving INLYTA in combination with avelumab to contact their healthcare provider immediately for signs or symptoms of cardiovascular events including but not limited to new or worsening chest discomfort, dyspnea, or peripheral edema [see

Embryo-Fetal Toxicity

Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of the pregnancy [see

Lactation

Advise patients not to breastfeed while taking INLYTA and for 2 weeks after receiving the last dose [see

Infertility

Advise males and females of reproductive potential that INLYTA may impair fertility [see

Concomitant Medications

Advise patients to inform their doctor of all concomitant medications, vitamins, or dietary and herbal supplements.


This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: June 2020    
PATIENT INFORMATION
INLYTA® (in-ly-ta)
(axitinib)
tablets
Important information: If your healthcare provider prescribes INLYTA for you to be taken with avelumab or pembrolizumab, also read the Medication Guide for avelumab or pembrolizumab.
What is INLYTA?
INLYTA is a prescription medicine used to treat kidney cancer that has spread or cannot be removed by surgery (advanced renal cell carcinoma or RCC):
  • in combination with avelumab or pembrolizumab as your first treatment.
  • alone when 1 prior drug treatment regimen for your RCC has not worked.
It is not known if INLYTA is safe and effective in children.
Before taking INLYTA, tell your healthcare provider about all of your medical conditions, including if you:
  • have high blood pressure
  • have thyroid problems
  • have liver problems
  • have a history of blood clots in your veins or arteries (types of blood vessels), including stroke, heart attack, or change in vision
  • have any bleeding problems
  • have a history of heart problems, including heart failure
  • have an unhealed wound
  • plan to have surgery or have had a recent surgery. You should stop taking INLYTA for at least 2 days before planned surgery. See " What are the possible side effects of INLYTA?"
For females, tell your healthcare provider if you:
  • are pregnant or plan to become pregnant. Taking INLYTA during pregnancy can harm your unborn baby. You should not become pregnant during treatment with INLYTA.
  • are able to become pregnant. You should have a pregnancy test before you start treatment with INLYTA. Use effective birth control during treatment and for 1 week after your last dose of INLYTA. Talk to your healthcare provider about birth control methods that you can use to prevent pregnancy during this time.
  • are breastfeeding or plan to breastfeed. It is not known if INLYTA passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after your last dose of INLYTA.
For males with female partners who are able to become pregnant:
  • Use effective birth control during treatment and for 1 week after your last dose of INLYTA.
  • If your female partner becomes pregnant during your treatment with INLYTA, tell your healthcare provider right away.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INLYTA and certain other medicines can affect each other causing serious side effects.
Talk with your healthcare provider before you start taking any new medicine. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I take INLYTA?
  • Take INLYTA exactly as prescribed by your healthcare provider.
  • Your healthcare provider may change your dose if needed.
  • INLYTA can be taken with or without food.
  • Take INLYTA 2 times a day about 12 hours apart.
  • Swallow INLYTA tablets whole with a glass of water.
  • Your healthcare provider should check your blood pressure regularly during treatment with INLYTA.
  • If you vomit or miss a dose of INLYTA, take your next dose at your regular time. Do not take two doses at the same time.
  • If you take too much INLYTA, call your healthcare provider or go to the nearest hospital emergency room right away.
What should I avoid while taking INLYTA?
  • Do not drink grapefruit juice or eat grapefruit. Grapefruit may increase the amount of INLYTA in your blood.
What are the possible side effects of INLYTA?
INLYTA may cause serious side effects, including:
  • High blood pressure (hypertension). High blood pressure is common with INLYTA and may sometimes be severe. Your healthcare provider should check your blood pressure regularly during treatment with INLYTA. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure, lower your dose, or stop your treatment with INLYTA.
  • Blood clots in your veins or arteries. INLYTA can cause blood clots which can be serious, and sometimes lead to death. Get emergency help and call your healthcare provider if you get any of the following symptoms:
  • chest pain or pressure
  • pain in your arms, back, neck or jaw
  • shortness of breath
  • numbness or weakness on one side of your body
  • trouble talking
  • headache
  • vision changes
  • Bleeding. INLYTA can cause bleeding which can be serious, and sometimes lead to death. Call your healthcare provider right away or get medical help if you develop any of the following signs or symptoms:
    • unexpected bleeding or bleeding that lasts a long time, such as:
  • unusual bleeding from the gums
  • menstrual bleeding or vaginal bleeding that is heavier than normal
  • bleeding that is severe or you cannot control
  • pink or brown urine
  • red or black stools (looks like tar)
  • bruises that happen without a known cause or get larger
  • cough up blood or blood clots
  • vomit blood or your vomit looks like "coffee grounds"
    • unexpected pain, swelling, or joint pain
    • headaches, feeling dizzy or weak
  • Heart failure. Your healthcare provider should check you for signs or symptoms of heart failure regularly during treatment with INLYTA. Heart failure can be serious and can sometimes lead to death. Tell your healthcare provider if you have any of the following symptoms during your treatment with INLYTA:
  • tiredness
  • swelling of your stomach-area (abdomen), legs or ankles
  • shortness of breath
  • protruding neck veins
  • Tear in your stomach or intestinal wall (perforation). A tear in your stomach or intestinal wall can be serious and can sometimes lead to death. Get medical help right away if you get the following symptoms:
    • severe stomach-area (abdominal) pain or stomach-area pain that does not go away
    • vomit blood
    • red or black stools
  • Thyroid gland problems. Your healthcare provider should do blood tests to check your thyroid gland function before and during your treatment with INLYTA. Tell your healthcare provider if you have any of the following symptoms during your treatment with INLYTA:
  • tiredness that worsens or that does not go away
  • feeling hot or cold
  • your voice deepens
  • weight gain or weight loss
  • hair loss
  • muscle cramps and aches
  • Risk of wound healing problems. Wounds may not heal properly during INLYTA treatment. Tell your healthcare provider if you plan to have any surgery before starting or during treatment with INLYTA.
    • You should stop taking INLYTA at least 2 days before planned surgery.
    • Your healthcare provider should tell you when you may start taking INLYTA again after surgery.
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS). A condition called reversible posterior leukoencephalopathy syndrome (RPLS) can happen during treatment with INLYTA. Call your healthcare provider right away if you get:
  • headache
  • seizures
  • weakness
  • confusion
  • high blood pressure
  • blindness or change in vision
  • problems thinking
  • Protein in your urine. Your healthcare provider should check your urine for protein before and during your treatment with INLYTA. If you develop protein in your urine, your healthcare provider may decrease your dose of INLYTA or stop your treatment.
  • Liver problems. Your healthcare provider will do blood tests before and during your treatment with INLYTA. Your healthcare provider may delay or stop your treatment with INLYTA if you develop severe liver problems.
  • Heart problems. When INLYTA is used with the medicine avelumab, severe heart problems can happen and can lead to death. Your healthcare provider will check you for heart problems during your treatment with INLYTA. Tell your healthcare provider right away or get medical help if you have any of the following symptoms:
  • swelling of your stomach-area, legs, hands feet or ankles
  • shortness of breath
  • nausea or vomiting
  • chest discomfort, including pain or pressure
  • weight gain
  • pain or discomfort in your arms, back, neck, or jaw
  • breaking out in a cold sweat
  • feeling lightheaded or dizzy
The most common side effects of INLYTA with avelumab include:
  • diarrhea
  • feeling tired
  • muscle and bone pain
  • nausea
  • mouth sores
  • rash, redness, itching, or peeling of your skin on your hands and feet
  • hoarseness
  • decreased appetite
  • low levels of thyroid hormone
  • rash
  • liver problems
  • cough
  • shortness of breath
  • stomach-area (abdomen) pain
  • headache
The most common side effects of INLYTA with pembrolizumab include:
  • diarrhea
  • feeling tired or weak
  • liver problems
  • low levels of thyroid hormone
  • decreased appetite
  • rash, redness, itching or peeling of your skin on your hands and feet
  • nausea
  • mouth sores or swelling of the lining of the mouth, nose, eyes, throat, intestines, or vagina
  • hoarseness
  • rash
  • cough
  • constipation
The most common side effects of INLYTA when used alone include:
  • diarrhea
  • feeling tired or weak
  • decreased appetite
  • nausea
  • hoarseness
  • rash, redness, itching or peeling of your skin on your hands and feet
  • decreased weight
  • vomiting
  • constipation
INLYTA may cause fertility problems in males and females, which may affect your ability to have a child. Talk to your healthcare provider if this is a concern for you.
These are not all of the possible side effects of INLYTA.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store INLYTA?

Store INLYTA at room temperature between 68°F to 77°F (20°C to 25°C).

General information about the safe and effective use of INLYTA.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use INLYTA for a condition for which it was not prescribed. Do not give INLYTA to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about INLYTA that is written for health professionals.
What are the ingredients in INLYTA?
Active ingredient: axitinib
Inactive ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and Opadry® II red 32K15441. The Opadry II red 32K15441 film coating contains: lactose monohydrate, HPMC 2910/Hypromellose 15cP, titanium dioxide, triacetin (glycerol triacetate), and red iron oxide.

Logo

LAB-0439-6.0
For more information, go to www.inlyta.com or call 8770744-5675
This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.
Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event